Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT00508287
StatusCompleted
PhasePhase 1
SponsorBristol-Myers Squibb
Enrollment36 participants
DesignInterventional, Randomized, Crossover, Masking: Double
ConditionsType 2 Diabetes
InterventionsBMS-686117; Byetta; Placebo
StartAug 2007
Primary completionNov 2007
Study completionNov 2007
Results postedNot yet
Registry last updatedMar 16, 2009

Compounds on this site that cite this trial

What the registry says the trial is about

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Safety: incidence of adverse eventsfrom subject enrollment to study discharge

2 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.

More trials of ATX-304

Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.

Share thisFacebookXEmail